Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Change in Cash (2016 - 2025)

Historic Change in Cash for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to -$2.6 million.

  • Aytu Biopharma's Change in Cash fell 99827.59% to -$2.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $9.6 million, marking a year-over-year increase of 100782.51%. This contributed to the annual value of $10.9 million for FY2025, which is 46743.87% up from last year.
  • Aytu Biopharma's Change in Cash amounted to -$2.6 million in Q4 2025, which was down 99827.59% from $1.7 million recorded in Q3 2025.
  • In the past 5 years, Aytu Biopharma's Change in Cash registered a high of $12.8 million during Q2 2025, and its lowest value of -$15.5 million during Q1 2021.
  • In the last 5 years, Aytu Biopharma's Change in Cash had a median value of -$378500.0 in 2023 and averaged -$1.6 million.
  • Examining YoY changes over the last 5 years, Aytu Biopharma's Change in Cash showed a top increase of 509471.54% in 2025 and a maximum decrease of 106320.35% in 2025.
  • Quarter analysis of 5 years shows Aytu Biopharma's Change in Cash stood at -$5.3 million in 2021, then increased by 18.42% to -$4.3 million in 2022, then soared by 89.91% to -$435000.0 in 2023, then surged by 166.67% to $290000.0 in 2024, then plummeted by 998.28% to -$2.6 million in 2025.
  • Its Change in Cash was -$2.6 million in Q4 2025, compared to $1.7 million in Q3 2025 and $12.8 million in Q2 2025.